Mandate

VINGE ADVISES WILLIS IN ACQUISITION OF MAX MATTHIESSEN

June 13, 2014

Vinge assists global risk adviser, insurance and reinsurance broker Willis Group Holdings plc in connection with its acquisition of a controlling stake in Max Matthiessen. Willis acquires approximately 75 % of the Swedish employee benefits advisor for approximately SEK 1.357 billion from Altor Fund III (50 %) and employees (25 %). Approximately 25 % is retained by employees.
 
Willis is listed on NYSE and operates on every continent with more than 18,000 employees in over 400 offices. Willis Sweden has 140 employees in four offices and is headquartered in Stockholm.
 
Max Matthiessen operates in retirement savings, health plans and personal insurance. The company has around 420 employees in 23 locations across Sweden. Gross turnover in 2013 exceeded SEK 1 billion. The combined business of Willis and Max Matthiessen will create the biggest risk adviser and broker in the Nordic region.
 
The acquisition is conditional upon customary regulatory approvals and conditions to closing.
 
Vinge’s team consisted of among others responsible partner Carl Gustaf De Geer, partner Malin Ohlin, project manager Peter Sundgren and associates Filip Brosset and Sofie Bjärtun (M&A), as well as associates Axel Hedberg (financial regulatory), Nina Farrahi (compliance), Emil Fahlén Godö (competition law) and Evelina Tejle (employment law).

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025